As an oncogene, LIFR contributes to the subsequent activation of STAT3 and AKT pathways in prostate cancer, inducing the expression of a series of proliferation-related and transfer genes (Shao et al., 2019; Zhang et al., 2020). This evidence concerns the gene STAT3 and prostate carcinoma.